Conversion Therapy of RAS/BRAF Wild-Type Colorectal Cancer Patients With Initially Unresectable Liver Metastases

Evidence suggests that the addition of cetuximab or bevacizumab to doublet regimens could improve response rate and resectability rate of liver metastases and survival in colorectal liver metastases (CRLM). Moreover, it is observed that FOLFOXIRI yields higher response and resection rates compared with doublet regimens. However, which is better in conversion therapy of RAS/BRAF wild-type initially unresectable CRLM, FOLFOXIRI plus cetuximab or bevacizumab, remains unknown. In this study, RAS/BRAF wild-type colorectal cancer patients with initially unresectable liver-only metastases, as prospe

Trial Details

NCT ID
NCT04687631
Phase
PHASE3
Sponsor
Fudan University
Status
RECRUITING
Cancer Type
Colon Cancer Colorectal Cancer
Interventions
  • mFOLFOXIRI plus Cetuximab
  • mFOLFOXIRI Plus Bevacizumab
Locations (sample)
  • Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

  • The primary tumor was confirmed by histology as colorectal adenocarcinoma
  • Initially unresectable liver metastases suggested by MDT
  • RAS/BRAF gene wild-type states
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colon Cancer Colorectal Cancer Trials on Trialify →